<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR55">
 <label>55.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Goldberg</surname>
    <given-names>SB</given-names>
   </name>
   <name>
    <surname>Gettinger</surname>
    <given-names>SN</given-names>
   </name>
   <name>
    <surname>Mahajan</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Chiang</surname>
    <given-names>AC</given-names>
   </name>
   <name>
    <surname>Herbst</surname>
    <given-names>RS</given-names>
   </name>
   <name>
    <surname>Sznol</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial</article-title>
  <source>Lancet Oncol</source>
  <year>2016</year>
  <volume>17</volume>
  <fpage>976</fpage>
  <lpage>983</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(16)30053-5</pub-id>
  <?supplied-pmid 27267608?>
  <pub-id pub-id-type="pmid">27267608</pub-id>
 </element-citation>
</ref>
